Raltegravir，以前称为MK-0518，是一种HIV-1整合酶链转移抑制剂，体外对多耐药性HIV-1和CCR5嗜性及CXCR4嗜性的HIV-1有抑制作用。对这些分子的结构进行修饰，以得到对野生型病毒及选择突变病毒效力最大的的HIV-整合酶抑制剂，并且优化临床前物种中的选择性、药代动力学和代谢特征。Raltegravir源于5,6 –二羟基嘧啶-4-甲酰胺和N-甲基-4-羟基嘧啶酮-甲酰胺的进化。Raltegravir具有强效的抗逆转录病毒作用，10天的单一治疗之后，HIV-1 RNA浓度从基线水平平均减少约2 log10 拷贝每毫升。

参考文献：
Beatriz Grinsztejn, Dr Bach-Yen Nguyen, Christine Katlama, Jose M Gatell, Adriano Lazzarin, Daniel Vittecoq, Charles J Gonzalez, Joshua Chen, Charlotte M Harvey, Robin D Isaacs.  Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Then Lancet. 2007. 369(9569): 1261–1269.
Vincenzo Summa, Alessia Petrocchi, Fabio Bonelli, Benedetta Crescenzi, Monica Donghi, Marco Ferrara, Fabrizio Fiore, Cristina Gardelli, Odalys Gonzalez Paz, Daria J.  Hazuda, Philip Jones, Olaf Kinzel, Ralph Laufer, Edith Monteagudo, Ester Muraglia, Emanuela Nizi, Federica Orvieto, Paola Pace, Giovanna Pescatore, Rita Scarpelli, Kara Stillmock, Marc V. Witmer, Michael Rowley. Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection. J. Med. Chem., 2008, 51 (18), pp 5843–5855.